Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 1042-1047

  Yamamoto, Nobuyuki ^a   Nishiwaki, Yutaka ^b   Negoro, Shunichi ^c   Jiang, Haiyi ^d   Itoh, Yohji ^d   Saijo, Nagahiro ^e   Fukuoka, Masahiro ^e  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d ASTRAZENECA   (United Kingdom)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Epidermal growth factor receptor tyrosine kinase inhibitors; Gefitinib; Landmark analysis; NSCLC

Indexed keywords

DOCETAXEL; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TAXOID;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77954425780     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181da36db     Document Type: Article

References (17)

1. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
2. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
4. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
5. Kelly K. The benefits of achieving stable disease in advanced lung cancer. Oncology (Williston Park) 2003;17:957-963.
6. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol 2006;1:684-691. (Pubitemid 47163957)
7. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002;38:1817-1823. (Pubitemid 35256090)
8. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26:463-467. (Pubitemid 351171700)
9. Yamamoto N, Nambu Y, Fujimoto T, et al. A Landmark Point Analysis with Cytotoxic Agents for Advanced NSCLC. J Thorac Oncol 2009;4: 697-701.
10. Tsujino K, Kawaguchi T, Kubo A, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009;4:994-1001.
11. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised phase III trial (INTEREST). Lancet 2008;372:1809-1818.
12. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-4252.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
14. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26:3913-3915.
15. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15:4493-4498.
16. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
17. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.